7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T9845 | Thrombin inhibitor 5 | ||
Thrombin inhibitor 5 (compound 385) is a thrombin inhibitor with IC 50s ranging from 0.1 μM to 1 μM. Thrombin inhibitor 5 can be used for venous thromboembolism research[1]. | |||
T7496 | Thrombin Receptor Activator for Peptide 5 (TRAP-5) | Thrombin Receptor Activator for Peptide | Protease-activated Receptor |
Thrombin Receptor Activator for Peptide 5 (TRAP-5), also known as Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), is employed in coronary heart disease (CHD) research. | |||
T10951 | Dabigatran ethyl ester hydrochloride | Others , Thrombin | |
Dabigatran ethyl ester hydrochloride is an effective inhibitor of ribosyl dihydronicotinic acid amide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and is a thrombin inhibitor. | |||
T72322 | R 59-022 hydrochloride | DKGI-I hydrochloride,Diacylglycerol kinase inhibitor I hydrochloride,DKGI-I hydrochloride ; Diacylglycerol kinase inhibitor I hydrochloride | 5-HT Receptor , PKC |
R 59-022 hydrochloride (DKGI-I hydrochloride) is a 5-HT Receptor antagonist that activates protein kinase C (PKC).R 59-022 hydrochloride is a DGK inhibitor (IC50:2.8 µM) that inhibits the phosphorylation of OAG to OAPA.R... | |||
T16709 | R 59-022 | Diacylglycerol kinase inhibitor I,DKGI-I | Others |
R 59-022 is a 5-HTR antagonist and activates protein kinase C (PKC). R 59-022 is a diacylglycerol kinase inhibitor (IC50=2.8 μM). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits ... | |||
T36777 | Thrombin Receptor Agonist Peptide (trifluoroacetate salt) | ||
Thrombin receptor agonist peptide (TRAP-14) is a 14-amino acid peptide agonist of the α-thrombin receptor. It induces aggregation of washed platelets as well as platelets in citrated and hirudin plasma. TRAP-14 (100 μM) ... | |||
T75242 | Bivalirudin TFA | ||
Bivalirudin TFA, a synthetic 20-residue peptide, serves as a reversible inhibitor of thrombin. Its IC50 value highlights its target specificity in vitro, where, combined with Eptifibatide (8 mg/mL) at a low concentration... |